SCHEMBL417476

SCHEMBL417476

COC(=O)c1cc(Cl)ccc1NC(=O)c1ccc(I)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 6/20 0.56
HPGD P15428 4/20 0.55
HSD17B10 Q99714 1/20 0.55
KMT2A Q03164 4/20 0.52
MEN1 O00255 2/20 0.52
PKM P14618 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.51
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
TSHR P16473 1/20 0.50
NPC1 O15118 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
RAB9A P51151 1/20 0.50
F10 P00742 1/20 0.50
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418492 0.85 AKR1C4 (0.57) SERPINE1HPGDHSD17B10KMT2AMEN1
SCHEMBL6349535 0.84 SERPINE1 (0.74) SERPINE1HSD17B10KMT2AMEN1KDM4E
SCHEMBL2878827 0.83 KDM4E (0.61) HPGDKMT2AMEN1NPSR1ALDH1A1
SCHEMBL417055 0.83 SERPINE1 (0.80) SERPINE1HPGDHSD17B10KMT2AMEN1
SCHEMBL6708107 0.82 F10 (0.56) SERPINE1HPGDHSD17B10KMT2AMEN1
SCHEMBL419182 0.81 SERPINE1 (0.77) SERPINE1KMT2AMEN1NPSR1ALDH1A1
SCHEMBL3619892 0.81 KMT2A (0.67) HPGDHSD17B10KMT2AMEN1PKM
SCHEMBL7036191 0.81 PPARG (0.57) HPGDKMT2AMEN1ALDH1A1KDM4E
SCHEMBL7036001 0.81 KDM4E (0.69) HPGDHSD17B10KMT2AMEN1NPSR1
SCHEMBL418773 0.80 SERPINE1 (0.77) SERPINE1HPGDHSD17B10NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885HPGD 904/4885HSD17B10 1809/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885HPGD 904/4885HSD17B10 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.